Sorafenib extends survival in differentiated thyroid cancer
June 2, 2013|Internal Medicine News
Author and Disclosure Information
AT THE ASCO ANNUAL MEETING 2013
CHICAGO – A new trial has found that sorafenib may help extend the survival of patients with differentiated thyroid cancer. In the phase-III DECISION trial, progression-free survival was extended by 5.8 months in patients treated with placebo and by 10.8 months in patients treated with sorafenib.
Dr. Marcia Brose discusses the new trial results in an interview at the annual meeting of the American Society of Clinical Oncology.